Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002)

A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS exon 2, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese. Osaka Gastrointestinal cancer chemotherapy Study Group:（OGSG1001）

A randomized phase II factorial design trial of CPT-11 versus PTX versus each combination with S-1 in patients with advanced gastric cancer refractory to S-1: Final results of OGSG0701

Five-year outcome of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy (OGSG0604)

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)　

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)

Multicenter phase II trial of adjuvant S-1 plus Docetaxel for 6 months in patients with pathological stage III gastric cancer (OGSG1002)

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: OGSG1203 (HERBIS-5)

Effects of an oral elemental nutrition supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: a phase II study (OGSG1108)

A phase II study to examine the effectiveness of nutritional support with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with S-1 (OGSG 1108)